Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Aralez Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Product Name : Blexten
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Aralez Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...
Product Name : Suvexx
Product Type : Other Small Molecule
Upfront Cash : $2.0 million
December 21, 2020
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Orion Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
